Velocity Pharmaceutical Development, Llc

VPD’s strategy is to create, invest in, and manage a portfolio of “project-focused companies,” each of which contains a single drug candidate acquired from a third party. VPD designs and executes the clinical development program for each of these drug candidates. VPD acquires rights to individual therapeutic drug candidates from biotechnology companies, pharmaceutical companies and academia, and invests in their development through clinical proof-of-concept (generally demonstration of human safety and efficacy in phase 2a trials). Following proof-of-concept, VPD seeks to sell each drug asset to a major pharmaceutical company. There is a robust demand by pharmaceutical acquirers for products with key human clinical data. Our model provides partners with a compelling alternative strategy for the development of their drug candidates. By partnering with VPD, the owner of a drug candidate can achieve the funding needed to take the drug candidate to clinical proof-of-concept while accessing a world-class team to design and oversee the development program. The contributor of the drug candidate receives equity in the company created to house its drug program and benefits from the ultimate financial upside upon clinical success and sale of that company to a pharmaceutical company. The Velocity model is much more efficient than traditional company-based drug development because it avoids the cost and time of building a separate management team and infrastructure around each program.